Denali Therapeutics (DNLI) Leases (2019 - 2025)
Historic Leases for Denali Therapeutics (DNLI) over the last 7 years, with Q3 2025 value amounting to $49.4 million.
- Denali Therapeutics' Leases rose 2781.96% to $49.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.4 million, marking a year-over-year increase of 2781.96%. This contributed to the annual value of $47.5 million for FY2024, which is 8248.23% up from last year.
- According to the latest figures from Q3 2025, Denali Therapeutics' Leases is $49.4 million, which was up 2781.96% from $47.4 million recorded in Q2 2025.
- Over the past 5 years, Denali Therapeutics' Leases peaked at $50.2 million during Q1 2025, and registered a low of $24.5 million during Q2 2024.
- Over the past 5 years, Denali Therapeutics' median Leases value was $30.7 million (recorded in 2021), while the average stood at $33.6 million.
- Its Leases has fluctuated over the past 5 years, first plummeted by 1445.75% in 2023, then skyrocketed by 9834.45% in 2025.
- Over the past 5 years, Denali Therapeutics' Leases (Quarter) stood at $30.7 million in 2021, then dropped by 1.0% to $30.4 million in 2022, then decreased by 14.42% to $26.0 million in 2023, then soared by 82.48% to $47.5 million in 2024, then rose by 4.03% to $49.4 million in 2025.
- Its Leases was $49.4 million in Q3 2025, compared to $47.4 million in Q2 2025 and $50.2 million in Q1 2025.